Get the Stockscreener App
2.37
3.66%
-0.09
After Hours:
2.40
0.03
+1.27%
Immunitybio Inc stock is traded at $2.37, with a volume of 7.04M.
It is down -3.66% in the last 24 hours and down -7.78% over the past month.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
See More
Previous Close:
$2.46
Open:
$2.37
24h Volume:
7.04M
Relative Volume:
0.76
Market Cap:
$2.09B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-2.4433
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
-17.13%
1M Performance:
-7.78%
6M Performance:
-31.30%
1Y Performance:
-50.52%
1-Day Range:
$2.335
$2.42
1-Week Range:
$2.335
$2.9099
52-Week Range:
$1.83
$7.48
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.37 | 2.34B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
What are analysts’ price targets for ImmunityBio Inc. in the next 12 monthsFinancial News Updates For Consistent Profits - jammulinksnews.com
ImmunityBio’s Innovative Approach to Glioblastoma: A Promising Clinical Update - TipRanks
ImmunityBio’s Innovative Immunotherapy Trial: A Potential Game-Changer in Cancer Treatment - TipRanks
Immunitybio (IBRX) Targets $80 Million Capital Raise for Business Operations - Insider Monkey
ImmunityBio, Inc. (IBRX) Gains UK Approval for ANKTIVA in Bladder Cancer - Insider Monkey
ImmunityBio Investors Nab Initial OK On Derivative Suit Deal - Law360
ImmunityBio Investor Settlement Over Cancer Drug Gets First Nod - Bloomberg Law News
Will ImmunityBio Inc. continue its uptrendTop Performing Stock Insights Released Daily - metal.it
ImmunityBio Bets Big On Next-Gen Cancer Immunotherapy - Finimize
Trend analysis for ImmunityBio Inc. this weekEntry Zone Strategy for Consistent Profit Shared - metal.it
How ImmunityBio Inc. stock reacts to Fed policy changesDaily Momentum Screener With Alerts Launched - metal.it
Published on: 2025-07-29 08:31:58 - metal.it
Natural Killer Cell Therapies Clinical Trials, Companies, - openPR.com
How does ImmunityBio Inc. compare to its industry peersDiscover breakthrough investment opportunities - jammulinksnews.com
What is ImmunityBio Inc. company’s growth strategyMaximize your portfolio’s growth with expert tips - jammulinksnews.com
Is ImmunityBio Inc. a growth stock or a value stockCapitalize on emerging market opportunities - jammulinksnews.com
What institutional investors are buying ImmunityBio Inc. stockAchieve rapid financial growth with expert help - jammulinksnews.com
Published on: 2025-07-28 00:26:40 - jammulinksnews.com
When is ImmunityBio Inc. stock expected to show significant growthInvest confidently with professional market insights - jammulinksnews.com
ImmunityBio’s Stock Soars: Buy or Sell? - timothysykes.com
ImmunityBio (IBRX) Secures $80M Through Direct Offering | IBRX S - GuruFocus
Everest Medicines raises $200M; Epirium Bio targets $55M Series B - Endpoints News
ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates - BioSpace
ImmunityBio announces $80M registered direct offering - TipRanks
What analysts say about ImmunityBio Inc. stockHigh-yield investments - PrintWeekIndia
ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors - Lelezard
ImmunityBio Announces $80 Million Securities Purchase - TipRanks
ImmunityBio's Q2 Preliminary Revenue: A Strategic Inflection Point in the Biotech Immune Therapeutics Sector - AInvest
ImmunityBio (IBRX) Achieves Significant Revenue Growth in Q2 2025 | IBRX Stock News - GuruFocus
ImmunityBio's Q2 Earnings and Revenue Growth: Assessing the Path to Sustainable Value Creation - AInvest
Is ImmunityBio Inc. a good long term investmentMarket-leading profit generation - Autocar Professional
ImmunityBio’s (IBRX) ANKTIVA Gets Approved by UK’s Medicines and Healthcare Regulatory Agency - MSN
What drives ImmunityBio Inc. stock priceConsistently high yield - jammulinksnews.com
LA Times Going Public? Patrick Soon-Shiong Plans Green Bay-Style Ownership To 'Democratize' 143-Year-Old Paper - Benzinga
ImmunityBio: A High-Conviction Play on ANKTIVA's Expanding Indication and Immune-Boosting Platform - AInvest
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunitybio Inc Stock (IBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SOON-SHIONG PATRICK | See remarks |
Feb 22 '25 |
Option Exercise |
0.00 |
114,329 |
0 |
29,588,261 |
| Sachs David C. | Chief Financial Officer |
Feb 22 '25 |
Option Exercise |
0.00 |
40,650 |
0 |
241,480 |
| Adcock Richard | CEO & President |
Feb 22 '25 |
Option Exercise |
0.00 |
152,439 |
0 |
412,585 |
| Simon Barry J. | Director |
Feb 22 '25 |
Option Exercise |
0.00 |
15,243 |
0 |
3,249,024 |
| Simon Barry J. | Director |
Jan 22 '25 |
Option Exercise |
2.00 |
110,020 |
219,864 |
3,233,781 |
| Adcock Richard | CEO & President |
Dec 31 '24 |
Option Exercise |
0.00 |
34,483 |
0 |
277,621 |
| Sachs David C. | Chief Financial Officer |
Dec 31 '24 |
Option Exercise |
0.00 |
30,397 |
0 |
216,235 |
| LAUER REGAN J | Chief Accounting Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
21,031 |
0 |
115,365 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):